“Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”, FE, vol. 26, no. 1, Mar. 2025, doi: 10.7175/fe.v26i1.1574.